Pre-clinical Evaluation of Biomarkers for Early Detection of Nephrotoxicity Following Alpha-particle Radioligand Therapy

• Published in: bioRxiv : the preprint server for biology
• Main Authors: Li, Mengshi, Robles-Planells, Claudia, Liu, Dijie, Graves, Stephen A, Vasquez-Martinez, Gabriela, Mayoral-Andrade, Gabriel, Lee, Dongyoul, Rastogi, Prerna, Marks, Brenna M, Sagastume, Edwin A, Weiss, Robert M, Linn-Peirano, Sarah C, Johnson, Frances L, Schultz, Michael K, Zepeda-Orozco, Diana
• Format: Journal Article
• Language: English
• Published: United States 29.09.2023

Cancer treatment with alpha-emitter-based radioligand therapies (α-RLTs) demonstrates promising tumor responses. Radiolabeled peptides are filtered through glomeruli, followed by potential reabsorption of a fraction by proximal tubules, which may cause acute kidney injury (AKI) and chronic kidney disease (CKD). Because tubular cells are considered the primary site of radiopeptides' renal reabsorption and potential injury, the current use of kidney biomarkers of glomerular functional loss limits the evaluation of possible nephrotoxicity and its early detection. This study aimed to investigate whether urinary secretion of tubular injury biomarkers could be used as additional non-invasive sensitive diagnostic tool to identify unrecognizable tubular damage and risk of long-term α-RLTs nephrotoxicity. A bifunctional cyclic peptide, melanocortin ligand-1(MC1L), labeled with [ Pb]Pb-MC1L, was used for [ Pb]Pb-MC1L biodistribution and absorbed dose measurements in CD-1 Elite mice. Mice were treated with [ Pb]Pb-MC1L in a dose escalation study up to levels of radioactivity intended to induce kidney injury. The approach enabled prospective kidney functional and injury biomarker evaluation and late kidney histological analysis to validate these biomarkers. Biodistribution analysis identified [ Pb]Pb-MC1L reabsorption in kidneys with a dose deposition of 2.8, 8.9, and 20 Gy for 0.9, 3.0, and 6.7 MBq injected [ Pb]Pb-MC1L doses, respectively. As expected, mice receiving 6.7 MBq had significant weight loss and CKD evidence based on serum creatinine, cystatin C, and kidney histological alterations 28 weeks after treatment. A dose-dependent urinary Neutrophil gelatinase-associated lipocalin (NGAL, tubular injury biomarker) urinary excretion the day after [ Pb]Pb-MC1L treatment highly correlated with the severity of late tubulointerstitial injury and histological findings. urine NGAL secretion could be a potential early diagnostic tool to identify unrecognized tubular damage and predict long-term α-RLT-related nephrotoxicity.